Chinese Medical Firm Eyes Johnson & Johnson Diabetes Unit
Chinese medical test-developer Sinocare Inc. has confirmed its interest in potentially acquiring Johnson & Johnson’s diabetes care unit.
The Shenzhen-listed company — which makes blood sugar monitoring systems — said it has hired agencies to study a possible deal, but that there was no timeline and talks could be halted at any time.
The deal could fetch up to $4 billion, Reuters reported earlier this month, citing unnamed sources with direct knowledge of the discussions.
J&J’s diabetes business has been in decline since 2011. Revenue dropped 32% to $1.8 billion in 2016 from five years earlier.
The unit includes LifeScan Inc. — which makes blood glucose monitoring systems — and insulin device producers Animas and Calibra Medical Inc., both of which J&J acquired in 2012.
“We are actively looking at strategic options for diabetes,” said J&J Chief Executive Alex Gorsky during an earnings call on Tuesday.
J&J faces competition in nearly all areas of the diabetes care market — from Bayer AG in pharmaceuticals, Novo Nordisk in injections, and local competitors in several markets where it operates, an industry professional with knowledge of J&J’s diabetes business told Caixin. Sinocare, for instance, is a leading maker of blood glucose monitoring devices in the China market.
Sinocare has been active in the industry in recent years. It acquired an 80% stake in a Beijing diabetes hospital in 2014. A year later, it offered to buy the diabetes device unit of Bayer, only to lose the bid to Panasonic Healthcare Holdings Co. Ltd. In 2016, Sinocare bought U.S.-based Nipro Diagnostics Inc. for 1.7 billion yuan ($270 million), and PTS Diagnostics, which makes diabetes care devices, for $110 million.
Trading of Sinocare shares was halted a week ago, after media reports surfaced about its potential bid, which the reports said was potentially being done through a consortium that included China Jianyin Investment Ltd. (JIC), a unit of sovereign wealth fund China Investment Corp. But Sinocare refused to comment on whether JIC was part of the group, and JIC did not respond to a request from Caixin.
Sinocare shares were down 2.37% at close Thursday.
Diabetes is emerging as a national health crisis in China. Half of the country’s population has either prediabetes or diabetes, according to a study by the Journal of the American Medical Association.
Contact reporter Coco Feng (email@example.com)
Dec 14 04:16
Dec 14 04:48
Dec 13 16:21
Dec 13 14:30
Dec 13 14:18
Dec 13 14:43
Dec 13 11:37
Dec 13 10:13
Dec 13 06:16
Dec 13 04:49
Dec 12 18:46
Dec 12 16:47
Dec 12 14:15
Dec 12 14:13
Dec 12 14:37
- 1JD.com’s Richard Liu Steps Down From Key Positions, but Retains Control
- 2In Depth: How the Queen of Gree Won, Again
- 3Another Local Government Financing Vehicle Fails to Pay Bond Interest
- 4China’s Curing Cancer Faster and Cheaper Than Anywhere Else
- 5 In Depth: China’s Private Sector Support Comes at a Cost
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas